The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

NCT00766948 | Active Not Recruiting

• 1 other identifier: HSC# 08-5022
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 3

Brief Summary

By creating a neurogenebank from Parkinson's disease patients' blood donations we will ultimately be able to define genes for Parkinson's disease and other neurological conditions.

Conditions

Parkinson's Disease

Outcome Measures

Primary Outcomes (1)

• Neurogenetic databank

  initiate a Parkinson's disease neurogenetic databank by obtaining blood samples in order to define genes for Parkinson's disease and other neurological conditions.

  Study completion

Study Arms (1)

No Treatment

Other: There is no intervention, this is a biorepository.

Interventions

There is no intervention, this is a biorepository. OTHER

There are no interventions in this study.

No Treatment

Eligibility Criteria

• Age: 30 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients 30 years of age or older with the diagnosis idiopathic Parkinson's disease

You may qualify if:

• Is age 30 years or older at the time of onset of Parkinson's
• Has been diagnosed with idiopathic Parkinson's Disease by a Scripps Neurologist
• Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented or have legal representative/guardian willing to do so
• Able to understand and grant informed consent or have a legal representative/ guardian who is able to do so

You may not qualify if:

• Patient has been previously enrolled in The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
• If a blood draw would be contraindicated for any reason
• Has a significant chronic medical condition (i.e. CVA, hepatic encephalopathy) which, in the investigator's option, may interfere with the patient's optimal participation in the study
• Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
• Has undergone ECT within 90 days preceding enrollment in the study

Sponsors & Collaborators

• Scripps Translational Science Institute: lead
• Scripps Health: collaborator
• The Scripps Research Institute: collaborator

Study Sites (3)

Scripps Clinic, Torrey Pines

La Jolla, California, 92037, United States

Location

Scripps Translational Science Institute

La Jolla, California, 92037, United States

Location

The Scripps Research Institute

La Jolla, California, 92037, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood or Saliva

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Cinnamon Bloss, PhD

  Scripps Translational Science Institute and Genomic Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: October 2, 2008
• First Posted: October 6, 2008
• Study Start: August 1, 2008
• Primary Completion (Estimated): August 1, 2030
• Study Completion (Estimated): August 1, 2030
• Last Updated: January 16, 2025

Record last verified: 2025-01

Locations

US (3)